Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 365.96M | 366.71M | 370.75M | 381.73M | 262.63M | 162.20M |
Gross Profit | 108.09M | 108.06M | 84.72M | 109.93M | 75.28M | 47.05M |
EBITDA | 25.14M | 23.90M | 24.65M | -610.00K | 9.01M | 4.15M |
Net Income | -1.82M | -4.50M | -5.41M | -34.35M | -22.73M | -18.18M |
Balance Sheet | ||||||
Total Assets | 218.31M | 223.54M | 231.89M | 264.54M | 282.82M | 156.11M |
Cash, Cash Equivalents and Short-Term Investments | 8.69M | 9.08M | 7.03M | 28.37M | 35.63M | 19.62M |
Total Debt | 81.87M | 82.63M | 97.86M | 135.22M | 125.57M | 82.19M |
Total Liabilities | 131.36M | 139.31M | 150.37M | 200.08M | 200.53M | 144.81M |
Stockholders Equity | 86.95M | 84.23M | 81.53M | 64.46M | 82.29M | 11.30M |
Cash Flow | ||||||
Free Cash Flow | 23.95M | 29.88M | 18.68M | 8.72M | 153.00K | -1.73M |
Operating Cash Flow | 31.78M | 37.99M | 27.38M | 22.33M | 7.27M | 229.00K |
Investing Cash Flow | -9.15M | -7.92M | -12.31M | -16.60M | -93.18M | -4.17M |
Financing Cash Flow | -21.16M | -28.02M | -36.40M | -12.99M | 101.91M | 23.50M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | 1.19B | 14.46 | 55.86% | 3.52% | 8.68% | 39.93% | |
59 Neutral | 269.31M | 2.09 | 105.57% | 2.49% | -35.35% | 948.72% | |
59 Neutral | 1.67B | 45.36 | 5.55% | 5.09% | 10.13% | 1.30% | |
53 Neutral | C$206.22M | ― | -2.17% | 0.58% | -0.16% | 75.25% | |
46 Neutral | 1.29B | -9.74 | -15.57% | ― | 20.36% | -186.10% | |
41 Neutral | 1.67M | -0.17 | 233.69% | ― | -22.61% | 7.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
CareRx Corporation reported its financial results for the second quarter of 2025, highlighting a growth in bed count to 91,062, which is expected to drive future growth. The company’s revenue for the quarter was $91.4 million, showing a slight increase from the previous quarter. Adjusted EBITDA also improved to $8.0 million due to increased bed servicing and cost-saving initiatives. Net income rose to $0.6 million, a significant improvement from a net loss in the same quarter of the previous year. The Ontario Ministry of Health’s decision to pause changes to long-term care pharmacy funding, which would have reduced professional fees, is expected to positively impact CareRx’s financial stability.
The most recent analyst rating on (TSE:CRRX) stock is a Hold with a C$2.25 price target. To see the full list of analyst forecasts on CareRx stock, see the TSE:CRRX Stock Forecast page.
CareRx Corporation announced it will host a conference call to discuss its second quarter 2025 financial results on July 31, 2025. This event will provide stakeholders with insights into the company’s financial performance and operational strategies, potentially impacting its market position and investor relations.
The most recent analyst rating on (TSE:CRRX) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on CareRx stock, see the TSE:CRRX Stock Forecast page.